Depletion of ZBTB38 increases the cytotoxic ability of DNMT inhibitors in different solid and hematological cancer cell lines by increasing the expression of Cyclin-Dependent Kinase Inhibitor 1C (CDKN1C) which opens up a new avenue to increase the therapeutic response to DNMT inhibitors (189). Here, CDKN1C is linked to hematopoietic and lymphoid cell neoplasm.